Data Analysis & Reporting Flashcards

A DOT audit reveals that an employer reported 90 random drug tests in their MIS but their average employee count qualified them for only 50 required tests. Which regulatory concern does this data pattern raise?

Answer: Over-testing is generally acceptable as long as selection remains truly random from the full pool

DOT regulations specify minimum random testing rates; exceeding that minimum by conducting more tests is permissible as long as the selection process is random from the full qualified pool.

When a split specimen (Bottle B) is tested at a second HHS-certified laboratory and the result is non-negative while Bottle A was positive, what is the correct MIS reporting outcome?

Answer: The MRO makes a final determination; the verified result is what gets reported

The MRO reviews all laboratory findings and issues a single verified result — that MRO-verified result is what the employer reports in MIS data, not individual laboratory sub-results.

A SAP reviewing industry data notices that opioid positives have increased 40% over three years in a transportation sector report. How should this trend inform a SAP's clinical evaluation approach?

Answer: It suggests heightened vigilance for prescription opioid misuse and should inform clinical questioning during evaluations

Population-level trends inform clinical practice; a SAP should use such data to strengthen inquiry into opioid use history and prescription drug misuse during individual evaluations.

An employer's MIS data shows all random alcohol tests had results of exactly 0.00 BAC. A DOT auditor flags this as a data quality concern. What is the most likely reason for the concern?

Answer: An unbroken string of 0.00 results may indicate tests are being conducted at predictable times, undermining randomness

While 0.00 BAC results are legitimate, a perfectly clean record with no variation may suggest testing occurs at predictable times (e.g., Monday mornings) when employees know to abstain, undermining the random deterrence purpose.

Which of the following correctly describes the purpose of 'blind performance testing' specimens in the context of DOT laboratory quality reporting?

Answer: They are quality control specimens submitted by employers to test laboratory accuracy without the lab knowing they are performance tests

Blind performance testing specimens are unidentified QC samples submitted by employers or C/TPAs to HHS labs to verify laboratory accuracy, with the lab unaware they are performance tests.

When analyzing return-to-duty testing data, which outcome most clearly demonstrates that a SAP's follow-up plan was clinically appropriate?

Answer: All follow-up tests were negative and the employee maintained continuous safety-sensitive employment without further violations

Sustained negative follow-up results combined with uninterrupted safety-sensitive employment without further violations is the strongest objective evidence that the SAP's clinical plan achieved its intended outcome.

A DOT-regulated employer switches from managing their own drug testing program to using a C/TPA. Who retains regulatory responsibility for the accuracy of MIS data submitted to the DOT operating administration?

Answer: The employer retains full regulatory responsibility regardless of C/TPA involvement

Under 49 CFR Part 40, the employer always retains full regulatory responsibility for their drug and alcohol testing program, including MIS data accuracy, even when a C/TPA administers the program.